THR-149 (pKal Inhibitor)

Preclinical studies and clinical observations show that inhibition of the enzymatic activity of plasma kallikrein is able to reduce the formation of bradykinins, which are key components in the induction of edema in the back of the eye. With less edema present in the eye, the inflammation and hyperpermeability stop deteriorating.

ThromboGenics intends to develop THR-149 as sustained release formulation, in order to generate a long-term effect of the product in the back of the eye.